| 摘要 |
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions. |
| 主权项 |
1. An antibody antigen binding domain which specifically binds human PD-1, and comprises complementarity determining region (CDR) 1, CDR2 and CDR3, in a combination selected from (a)-(o) as follows, wherein the antibody (Ab), heavy chain (HC) or light chain (LC) and CDR nomenclature system (Kabat, IMGT or composite) from which the CDR combinations derive are shown in the first column, and residues in bold text are Kabat system, and residues underlined are IMGT system:Ab,ChainSystemCDR1mu326GYTFTNYGMNHC(a)KabatSEQ ID NO: 17, res. 6-10(b)IMGTSEQ ID NO: 17, res. 1-8(c)Comp.SEQ ID NO: 17mu326RASESVDNYGYSFMHLC(d)KabatSEQ ID NO: 20(e)IMGTSEQ ID NO: 20, res. 4-13(f)Comp.SEQ ID NO: 20326-4A3GYTFTNYGMNHC(g)KabatSEQ ID NO: 17, res. 6-10(h)IMGTSEQ ID NO: 17, res. 1-8(i)Comp.SEQ ID NO: 17326-1GYTFTNYGMNHC(j)KabatSEQ ID NO: 17, res. 6-10(k)IMGTSEQ ID NO: 17, res. 1-8(l)Comp.SEQ ID NO: 17326-3B1GYTFTNYGMNHC(m)KabatSEQ ID NO: 17, res. 6-10(n)IMGTSEQ ID NO: 17, res. 1-8(o)Comp.SEQ ID NO: 17Ab,ChainSystemCDR2mu326WINNNNGEPTYAEEFKGHC(a)KabatSEQ ID NO: 18(b)IMGTSEQ ID NO: 18, res. 2-9(c)Comp.SEQ ID NO: 18mu326RASNLESLC(d)KabatSEQ ID NO: 21(e)IMGTSEQ ID NO: 21, res. 1-3(f)Comp.SEQ ID NO: 21326-4A3WINNNNAEPTYAQDFRGHC(g)KabatSEQ ID NO: 38(h)IMGTSEQ ID NO: 38, res.2-9(i)Comp.SEQ ID NO: 38326-1WINNNNGEPTYAQGFRGHC(j)KabatSEQ ID NO: 62(k)IMGTSEQ ID NO: 62, res. 2-9(l)Comp.SEQ ID NO: 62326-3B1WINNNNGEPTYAQDFRGHC(m)KabatSEQ ID NO: 63(n)IMGTSEQ ID NO: 63, res. 2-9(o)Comp.SEQ ID NO: 63Ab,ChainSystemCDR3mu326ARDVMDYHC(a)KabatSEQ ID NO: 19, res. 3-7(b)IMGTSEQ ID NO: 19(c)Comp.SEQ ID NO: 19mu326QQSKEYPTLC(d)KabatSEQ ID NO: 22(e)IMGTSEQ ID NO: 22(f)Comp.SEQ ID NO: 22326-4A3ARDVMDYHC(g)KabatSEQ ID NO: 19, res. 3-7(h)IMGTSEQ ID NO: 19(i)Comp.SEQ ID NO: 19326-1ARDVMDYHC(j)KabatSEQ ID NO: 19, res. 3-7(k)IMGTSEQ ID NO: 19(l)Comp.SEQ ID NO: 19326-3B1ARDVMDYHC(m)KabatSEQ ID NO: 19, res. 3-7(n)IMGTSEQ ID NO: 19(o)Comp.SEQ ID NO: 19. |
